Navigation Links
Clinical trial at GHSU Cancer Center targets advanced prostate cancer
Date:12/3/2012

AUGUSTA, Ga. Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

The trial, led by GHSU Cancer Center Director Samir N. Khleif, is the first in the country to investigate prostate cancer treatment combining Provenge with two other cancer-fighting drugs, CT-011 and cyclophosphamide. As the first FDA-approved immunotherapy treatment for prostate cancer, Provenge has been found to extend life expectancy of certain men with advanced prostate cancer by nearly 20 percent.

"Although the increased overall survival seen with Provenge treatment is a welcome advance in the treatment of prostate cancer, the goal of cancer therapy must be the eradication of disease," said Khleif. "Therefore, improvements can be made, and this clinical trial is intended to improve the current standard of care."

Provenge works by training the body's immune system to find and attack prostate cancer cells. Khleif's trial hopes to boost Provenge's effectiveness by combining it with two other drugs: CT-011, a type of antibody that reverses immune suppression caused by cancer, and cyclophosphamide, which in a low dose enhances the effect of Provenge and CT-011. Both have been safely used alone or in combination with other cancer therapies, but never for prostate cancer.

Preclinical animal studies in Khleif's lab found that the combination of Provenge with these two other drugs led to a significant increase in survival and complete tumor regression in more than 50 percent of mice. Based on these results, Dendreon Corporation, the makers of Provenge, and Khleif are collaborating on this first in human trial.

Khleif joined the GHSU Cancer Center as its Director after more than 22 years in the Cancer Vaccine Section at the National Cancer Institute. His lab focuses on research into vaccines to help the immune system target and eradicate cancers.

Prostate cancer is the most common cancer and the second leading cause of cancer deaths among men in most Western countries.


'/>"/>

Contact: Christen Carter
chrcarter@georgiahealth.edu
706-721-5733
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial at GHSU Cancer Center targets advanced prostate cancer
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: